Bizarre Patents
Smoking Cessation Lighter and Method
A lighter for tobacco products suppresses the urge to smoke by operant conditioning.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7879331 | Ultra-high yield intravenous immune globulin preparation An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs sodium citrate in two initial fractiona... | 02/01/2011 |
| 7879332 | Ultra-high yield intravenous immune globulin preparation An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs one or more salts from a group of salts... | 02/01/2011 |
| 7744890 | Methods and compositions with reduced opalescence Methods for reducing the opalescent appearance of a protein preparation by modifying the ionic strength of the preparation, as well as compositions, e.g., pharmaceutical compositions, of concentrated protein with decreased opalescence are disclosed. Purification met... | 06/29/2010 |
| 7662386 | Compositions and methods for WT1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that sp... | 02/16/2010 |
| 7611709 | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives Disclosed are applications of oligosaccharides/oligosaccharide mixtures for the production and stabilization of pharmaceutical compositions, chiefly powders, that contain antibodies or antibody derivatives as pharmaceutical active substance. The production of powder... | 11/03/2009 |
| 7413739 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments. ... | 08/19/2008 |
| 7368542 | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can... | 05/06/2008 |
| 7288254 | Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation The invention provides a method of treating diabetes in a subject, comprising administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population, and administering to the subject pancreatic islet cells from a donor. The immune tol... | 10/30/2007 |
| 7241592 | Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermi... | 07/10/2007 |
| 7186410 | Method for preparing human immunoglobulin concentrates for therapeutic use The invention concerns a method for preparing human immunoglobulin concentrates for therapeutic use, from plasma or a plasma fraction. The method comprises pre-purification and a single anion-exchange chromatography carried out at alkaline pH, thereby enabling the i... | 03/06/2007 |
| 7138120 | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products The present invention relates to a process for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction. Said process includes a number of steps of which the anion exchange chromatography and the cation exchange chromatography are pr... | 11/21/2006 |
| 7125552 | Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates The method for immune serum globulin purification relates to the purification of immune globulins from blood plasma with a high degree of efficiency and a high rate of recovery. The immune globulin source is Cohn's fraction I+II+III or II+III prepared from plasma or... | 10/24/2006 |
| 7041798 | Method for the chromatographic fractionation of plasma or serum, preparations, so obtained, and their use The invention relates to the fractionation of plasma or serum into at least one albumin fraction and one immunoglobulin fraction by hydrophobic interaction chromatography. The fractionation is carried out using an incremental salt gradient, especially an ammonium su... | 05/09/2006 |
| 7014847 | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The method comprises suppressing or otherwise inhibiting t... | 03/21/2006 |
| 6933286 | Therapeutic delivery compositions and methods of use thereof The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. In particular, compositions and methods us... | 08/23/2005 |
| 6893639 | Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates The method for immune serum globulin purification relates to the purification of immune globulins from blood plasma with a high degree of efficiency and a high rate of recovery. The immune globulin source is Cohn's fraction I+II+III or II+III prepared from plasma or... | 05/17/2005 |
| 6875848 | Process for the production of virus-inactivated human gammaglobulin G The gammaglobulin is extracted from a fraction isolated by fractionation with ethanol in the presence of a carbohydrate, and after reducing the content of contaminants with PEG, it is applied to an anionic resin exchange column, an effluent being obtained in which t... | 04/05/2005 |
| 6875432 | Reduced-viscosity concentrated protein formulations The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.... | 04/05/2005 |
| 6869605 | BAFF, inhibitors thereof and their use in the modulation of B-cell response The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists. ... | 03/22/2005 |
| 6849259 | Polyclonal antibody composition for treating allergy A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one o... | 02/01/2005 |
| 6800738 | Method for making humanized antibodies Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided. ... | 10/05/2004 |
| 6709655 | Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically ... | 03/23/2004 |
| 6686191 | Preparation of virally inactivated intravenously injectable immune serum globulin Method of reducing the anticomplement activity (ACA) resulting from viral inactivation treatment of a solution of antibodies, the method comprising contacting the solution with a trialkylphosphate, such as tri-n-butyl phosphate, and a detergent, such as s... | 02/03/2004 |
| 6646108 | Process for isolating IgG and IgA A method for the separation of IgG and IgA from an immunoglobulin-containing starting material is described, whereby the method is characterized in that (i) IgG and optionally IgA are adsorbed to a solid inorganic carrier material, (ii) IgA is isolated fr... | 11/11/2003 |
| 6565831 | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The method comprises suppressing or otherwise i... | 05/20/2003 |
| 6485932 | Composition comprising immunoglobulin Liquid compositions for intravenous administration that comprise an aqueous solution of immunoglobulin and methods of preparing such compositions are disclosed. The solution has a pH in the range of 5.0 to 5.8 and an ionic strength is the range 0.02 to 0.... | 11/26/2002 |
| 6485725 | Room temperature storable immunoglobulin preparation for intravenous injection A method for producing an immunoglobulin preparation for intravenous injection, which comprises the steps of: fractionating an immunoglobulin-containing solution with 4 to 10 w/v% of polyethylene glycol having a molecular weight of from 1,000 to 10,000, a... | 11/26/2002 |
| 6281336 | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products The present invention relates to a process for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction. Said process includes a number of steps of which the anion exchange chromatography and the cation exchange chromatogr... | 08/28/2001 |
| 6252055 | Concentrated antibody preparation Concentrated monoclonal antibody preparations for administration to humans are described in which the antibody is present at a concentration of greater than 100 mg/ml and as high as 350 mg/ml.... | 06/26/2001 |
| 6238664 | Process for stabilizing proteins An aqueous protein solution buffered with a potassium phosphate buffer, in which the ratio of potassium ions to sodium ions in the solution is at least 10:1, is resistant to the formation of protein aggregates and particles under conditions of freezing, t... | 05/29/2001 |
| 6165467 | Stabilized human monoclonal antibody preparation A stabilized human monoclonal antibody preparation containing 1 to 20 mg of D-mannitol per 1 mg of a human monoclonal antibody. This preparation is excellent in stability in a solution state, a freeze drying state and a freezing state, particularly stabil... | 12/26/2000 |
| 6159471 | Room temperature storable immunoglobulin preparation for intravenous injection A method for producing an immunoglobulin preparation for intravenous injection, which comprises the steps of: fractionating an immunoglobulin-containing solution with 4 to 10 w/v % of polyethylene glycol having a molecular weight of from 1,000 to 10,000, ... | 12/12/2000 |
| 6136312 | Method for producing an IgM preparation for intravenous application In the method for producing an immunoglobulin solution suitable for intravenous application with an IgM proportion of more than 5% by weight with respect to the immunoglobulin proportion, an IgM-containing immunoglobulin solution is treated with a proteas... | 10/24/2000 |
| 6090380 | Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin Pooled human immunoglobulin may be administered orally to rheumatoid arthritis patients to treat the rheumatoid arthritic condition of those patients. Oral administration of pooled human immunoglobulin can result in significant clinical improvement in the... | 07/18/2000 |
| 5972632 | Anticomplement activity assays Immunoassays for complement components, complement activation products or, preferably both, can be used to determine an acceptable level of anticomplement activity (AC) in plasma derived biologically active products intended for infusion into a mammal. In... | 10/26/1999 |
| 5871950 | Methods of treating autoimmune diseases and transplantation rejection The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of M... | 02/16/1999 |
| 5871736 | Liquid immunoglobulin formulations Immunoglobulin preparations, particularly liquid preparations of immunogllin G for intravenous infusion, are stabilized against dimer formation by the addition of one or more amphiphilic stabilizers. Preferred amphiphilic stabilizers are nicotinic acid d... | 02/16/1999 |
| 5750105 | Recombinant antibodies for human therapy Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use.... | 05/12/1998 |
| 5612033 | Methods of treatment using heat-treated IGM antibody preparations Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM immunoglobulin concentrates retain specific antigen binding... | 03/18/1997 |
| 5510465 | Heat-treated IgM antibody preparations Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM immunoglobulin concentrates retain specific antigen binding... | 04/23/1996 |
